Literature DB >> 33614476

A Review of Newly Diagnosed Glioblastoma.

Bryan Oronsky1, Tony R Reid2, Arnold Oronsky3, Navjot Sandhu4, Susan J Knox4.   

Abstract

Glioblastoma is an aggressive and inevitably recurrent primary intra-axial brain tumor with a dismal prognosis. The current mainstay of treatment involves maximally safe surgical resection followed by radiotherapy over a 6-week period with concomitant temozolomide chemotherapy followed by temozolomide maintenance. This review provides a summary of the epidemiological, clinical, histologic and genetic characteristics of newly diagnosed disease as well as the current standard of care and potential future therapeutic prospects.
Copyright © 2021 Oronsky, Reid, Oronsky, Sandhu and Knox.

Entities:  

Keywords:  brain tumors; cancer; glioblastoma; high-grade gliomas; radiation therapy

Year:  2021        PMID: 33614476      PMCID: PMC7892469          DOI: 10.3389/fonc.2020.574012

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  11 in total

1.  A multimodal domain adaptive segmentation framework for IDH genotype prediction.

Authors:  Hailong Zeng; Zhen Xing; Fenglian Gao; Zhigang Wu; Wanrong Huang; Yan Su; Zhong Chen; Shuhui Cai; Dairong Cao; Congbo Cai
Journal:  Int J Comput Assist Radiol Surg       Date:  2022-07-06       Impact factor: 3.421

2.  Aberrant Protein Glycosylation in Brain Cancers, with Emphasis on Glioblastoma.

Authors:  Livia Rosa-Fernandes; Sueli Mieko Oba-Shinjo; Janaina Macedo-da-Silva; Suely Kazue Nagahashi Marie; Giuseppe Palmisano
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

3.  Globularia alypum L. and Related Species: LC-MS Profiles and Antidiabetic, Antioxidant, Anti-Inflammatory, Antibacterial and Anticancer Potential.

Authors:  Maja Friščić; Roberta Petlevski; Ivan Kosalec; Josip Madunić; Maja Matulić; Franz Bucar; Kroata Hazler Pilepić; Željan Maleš
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-21

4.  Evaluation of 3-l- and 3-d-[18F]Fluorophenylalanines as PET Tracers for Tumor Imaging.

Authors:  Felicia Krämer; Benedikt Gröner; Chris Hoffmann; Austin Craig; Melanie Brugger; Alexander Drzezga; Marco Timmer; Felix Neumaier; Boris D Zlatopolskiy; Heike Endepols; Bernd Neumaier
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639

5.  Clinical Significance and Immune Landscape of a Pyroptosis-Derived LncRNA Signature for Glioblastoma.

Authors:  Zhe Xing; Zaoqu Liu; Xudong Fu; Shaolong Zhou; Long Liu; Qin Dang; Chunguang Guo; Xiaoyong Ge; Taoyuan Lu; Youyang Zheng; Lirui Dai; Xinwei Han; Xinjun Wang
Journal:  Front Cell Dev Biol       Date:  2022-02-10

Review 6.  Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy.

Authors:  Jang Hyun Park; Heung Kyu Lee
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

Review 7.  Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma.

Authors:  Jennifer K Matsui; Haley K Perlow; Alex R Ritter; Rituraj Upadhyay; Raju R Raval; Evan M Thomas; Sasha J Beyer; Clement Pillainayagam; Justin Goranovich; Shirley Ong; Pierre Giglio; Joshua D Palmer
Journal:  Biomedicines       Date:  2022-07-21

Review 8.  Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.

Authors:  Danijela Drakulic; Marija Schwirtlich; Isidora Petrovic; Marija Mojsin; Milena Milivojevic; Natasa Kovacevic-Grujicic; Milena Stevanovic
Journal:  Cells       Date:  2022-08-15       Impact factor: 7.666

9.  Identification of an IFN-β-associated gene signature for the prediction of overall survival among glioblastoma patients.

Authors:  Lijing Cheng; Meiling Yuan; Shu Li; Zhiying Lian; Junjing Chen; Weibiao Lin; Jianbo Zhang; Shupeng Zhong
Journal:  Ann Transl Med       Date:  2021-06

Review 10.  DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.

Authors:  Ola Rominiyi; Spencer J Collis
Journal:  Mol Oncol       Date:  2021-06-11       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.